These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Qi W; Schultes BC; Liu D; Kuzma M; Decker W; Madiyalakan R Hybrid Hybridomics; 2001; 20(5-6):313-24. PubMed ID: 11839249 [TBL] [Abstract][Full Text] [Related]
28. The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences. Agrawal B; Reddish MA; Christian B; VanHeele A; Tang L; Koganty RR; Longenecker BM Cancer Res; 1998 Nov; 58(22):5151-6. PubMed ID: 9823326 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon, and breast tissues. Cao Y; Karsten U; Hilgers J Tumour Biol; 1998; 19 Suppl 1():88-99. PubMed ID: 9422093 [TBL] [Abstract][Full Text] [Related]
30. Importance of hydropathic complementarity for the binding of the neuropeptide substance P to a monoclonal antibody: equilibrium and kinetic studies. Hanin V; Déry O; Boquet D; Sagot MA; Créminon C; Couraud JY; Grassi J Mol Immunol; 1997; 34(12-13):829-38. PubMed ID: 9464518 [TBL] [Abstract][Full Text] [Related]
31. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946 [TBL] [Abstract][Full Text] [Related]
32. Modulation of the antigenic peptide transporter TAP by recombinant antibodies binding to the last five residues of TAP1. Plewnia G; Schulze K; Hunte C; Tampé R; Koch J J Mol Biol; 2007 May; 369(1):95-107. PubMed ID: 17418234 [TBL] [Abstract][Full Text] [Related]
33. Monoclonal antipeptide antibodies: affinity and kinetic rate constants measured for the peptide and the cognate protein using a biosensor technology. Zeder-Lutz G; Altschuh D; Geysen HM; Trifilieff E; Sommermeyer G; Van Regenmortel MH Mol Immunol; 1993 Feb; 30(2):145-55. PubMed ID: 7679185 [TBL] [Abstract][Full Text] [Related]
36. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576 [TBL] [Abstract][Full Text] [Related]
37. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
39. Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity. Mazor Y; Keydar I; Benhar I Mol Immunol; 2005 Jan; 42(1):55-69. PubMed ID: 15488944 [TBL] [Abstract][Full Text] [Related]
40. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]